Andrew’s programme of research investigates the roles of cytokines in immune and haematopoietic disorders. He has defined and characterised how type-2 cytokine networks orchestrate the cellular response to pathogens and how dysregulation of these regulatory pathways can lead to diseases such as asthma and allergy. His identification of the cytokine interleukin-13 and the subsequent unearthing of its role in allergic asthma led to his discovery of type-2 innate lymphoid cells (ILC2). These lymphocytes secrete large quantities of cytokines and represent a new therapeutic target for intervention in inflammation and infection. More recently he has detailed the transcriptional regulators that restrict ILC2 development from lymphoid progenitors, and unearthed how ILC2 play critical roles in potentiating adaptive immunity.
Prior to his appointment at the LMB, he was a postdoctoral fellow at the MRC National Institute for Medical Research (UK) and subsequently a postdoctoral at DNAX Research Institute of Cellular and Molecular Biology (USA). He was elected as a Fellow of the Royal Society in 2017, and a Fellow of the Academy of Medical Sciences in 2011.